DE69637556D1 - Sulfat-Konjugate der Ursodeoxycholsäure und deren nützliche Verwendung bei entzündlichen Erkrankungen und anderen Anwendungen - Google Patents

Sulfat-Konjugate der Ursodeoxycholsäure und deren nützliche Verwendung bei entzündlichen Erkrankungen und anderen Anwendungen

Info

Publication number
DE69637556D1
DE69637556D1 DE69637556T DE69637556T DE69637556D1 DE 69637556 D1 DE69637556 D1 DE 69637556D1 DE 69637556 T DE69637556 T DE 69637556T DE 69637556 T DE69637556 T DE 69637556T DE 69637556 D1 DE69637556 D1 DE 69637556D1
Authority
DE
Germany
Prior art keywords
udca
sulfate
tauro
disulfate
glyco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637556T
Other languages
English (en)
Inventor
Kenneth D Setchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Application granted granted Critical
Publication of DE69637556D1 publication Critical patent/DE69637556D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
DE69637556T 1995-11-21 1996-11-19 Sulfat-Konjugate der Ursodeoxycholsäure und deren nützliche Verwendung bei entzündlichen Erkrankungen und anderen Anwendungen Expired - Lifetime DE69637556D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/560,992 US5763435A (en) 1995-11-21 1995-11-21 Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
PCT/US1996/018487 WO1997018816A2 (en) 1995-11-21 1996-11-19 Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications

Publications (1)

Publication Number Publication Date
DE69637556D1 true DE69637556D1 (de) 2008-07-17

Family

ID=24240215

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637556T Expired - Lifetime DE69637556D1 (de) 1995-11-21 1996-11-19 Sulfat-Konjugate der Ursodeoxycholsäure und deren nützliche Verwendung bei entzündlichen Erkrankungen und anderen Anwendungen

Country Status (15)

Country Link
US (2) US5763435A (de)
EP (1) EP0871452B1 (de)
JP (3) JP3836148B2 (de)
KR (1) KR19990071521A (de)
CN (2) CN101569632A (de)
AT (1) ATE397450T1 (de)
AU (1) AU709594B2 (de)
BR (1) BR9611606A (de)
CA (1) CA2238040C (de)
DE (1) DE69637556D1 (de)
EA (1) EA199800399A1 (de)
NO (2) NO317063B1 (de)
NZ (1) NZ323274A (de)
PL (1) PL186393B1 (de)
WO (1) WO1997018816A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
DE19645044A1 (de) * 1996-10-31 1998-05-07 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute
DE19906290A1 (de) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
EP1212064A2 (de) * 1999-03-09 2002-06-12 Max-Delbrück-Centrum Für Molekulare Medizin Verwendung von endotoxinhemmern zur behandlung von herzinsuffizienz and von kachexie
CA2406067A1 (en) * 2000-04-19 2001-11-01 Thomas Julius Borody Compositions comprising the combination of a bile acid and a fibrate for use in therapies for hyperlipidaemia-associated disorders
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
ITTO20020102A1 (it) * 2002-02-06 2003-08-06 Abc Ist Biolog Chem Spa Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.
CN100421656C (zh) * 2002-11-07 2008-10-01 明尼苏达大学评议会 乌索脱氧胆酸在制备治疗与出血相关的神经系统损伤的药物中的用途
ITMI20030822A1 (it) * 2003-04-18 2004-10-19 Erregierre Spa Processo per la preparazione dell'acido ursodesossicolico
EP2182856A2 (de) * 2007-08-08 2010-05-12 Brian J. Cavanaugh Verfahren und vorrichtung für ligaturnaht
EP2208497A1 (de) * 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Verwendung von Ursodesoxycholsäure (UDCA) zum Verbessern des allgemeinen Gesundheitszustands eines Tumorpatienten
IT1393095B1 (it) 2009-02-19 2012-04-11 Prodotti Chimici Alimentari Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato.
US8889840B2 (en) 2009-10-29 2014-11-18 Industry-Academic Cooperation Foundation, Yonsei University Vascular leakage inhibitor
JPWO2011096438A1 (ja) * 2010-02-03 2013-06-10 国立大学法人 東京大学 腸疾患の治療方法及び治療用医薬組成物
WO2013025840A1 (en) 2011-08-15 2013-02-21 Massachusetts Eye And Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
KR101953298B1 (ko) * 2017-07-18 2019-02-28 의료법인 성광의료재단 우르소데옥시콜산을 함유하는 염증성 질환 또는 척수 손상 예방 또는 치료용 조성물
JP2022534369A (ja) * 2019-05-31 2022-07-29 メタボロン，インコーポレイテッド 代謝物を検出するための質量分析アッセイ法
CN117949648A (zh) * 2024-03-26 2024-04-30 中国医学科学院北京协和医院 一种用于检测溃疡性结肠炎的标志物及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1221734B (it) * 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof

Also Published As

Publication number Publication date
AU7737796A (en) 1997-06-11
CA2238040A1 (en) 1997-05-29
CA2238040C (en) 2004-07-13
NO982281D0 (no) 1998-05-19
NO317063B1 (no) 2004-08-02
NO20042284L (no) 2004-06-02
NZ323274A (en) 2000-07-28
KR19990071521A (ko) 1999-09-27
EA199800399A1 (ru) 1998-12-24
CN101569632A (zh) 2009-11-04
WO1997018816A3 (en) 1997-06-26
EP0871452B1 (de) 2008-06-04
JP2011006445A (ja) 2011-01-13
WO1997018816A2 (en) 1997-05-29
CN1211185A (zh) 1999-03-17
MX9803988A (es) 1998-10-31
JP3836148B2 (ja) 2006-10-18
US6251884B1 (en) 2001-06-26
CN100556408C (zh) 2009-11-04
EP0871452A2 (de) 1998-10-21
AU709594B2 (en) 1999-09-02
PL326931A1 (en) 1998-11-09
JP2006117698A (ja) 2006-05-11
ATE397450T1 (de) 2008-06-15
BR9611606A (pt) 2000-10-24
JP2000500764A (ja) 2000-01-25
NO20042284D0 (no) 2004-06-02
JP5277221B2 (ja) 2013-08-28
US5763435A (en) 1998-06-09
NO982281L (no) 1998-07-08
PL186393B1 (pl) 2004-01-30
JP4630195B2 (ja) 2011-02-09

Similar Documents

Publication Publication Date Title
DE69637556D1 (de) Sulfat-Konjugate der Ursodeoxycholsäure und deren nützliche Verwendung bei entzündlichen Erkrankungen und anderen Anwendungen
Kojima et al. Comparative effects of three chelating agents on distribution and excretion of cadmium in rats
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
CY1124074T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
DE60302348D1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
BRPI0206641B8 (pt) uso de um inibidor da absorção de esteróis
BR9909908A (pt) Derivados de ácidos graxos de ácidos biliares e derivados de ácidos biliares
ATE400264T1 (de) Methoden zur behandlung von nierenversagen
DE60213404D1 (de) Verwendung von sulodexid zur behandlung von reizdarm
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
BR9608435A (pt) Metodo para medicação do sistema de controle inflatório e de reações inflamatórias adversas e para produção de composto para o tratamento da patologia de reações inflamatórias adversas.
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
Wollina et al. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix
KR940021064A (ko) 프레그네인 유도체의 사용 방법
CA2274943A1 (en) Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
Wan et al. Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein–carotid artery interposition grafts
Ishizaki et al. Effect of sodium tauroursodeoxycholate (UR-906) on liver dysfunction in bile duct-ligated rats
Palmer The significance of bile salts metabolism
US20070292533A1 (en) Copper lowering treatment of autoimmune diseases
PT1100481E (pt) Formulacoes farmaceuticas compreendendo dipropionato de beclometasona para o tratamento de doencas inflamatorias do intestino
Jähne et al. Intraoperative (hyperthermic) intraperitoneal chemotherapy—Considerations and aspects for the safe intra-and postoperative use of cytostatic agents
Gruen Iron uptake in human keratinocytes exposed to photodegraded nifedipine
Koziorowski et al. Ferritin in parkinsonian and control brains
Twedt Treatment of chronic hepatitis and management of biliary tract disorders
Toborek et al. Macrophage migration inhibitor factor (MIF) can induce oxidative injury and apoptotic cell death of spinal cord neurons

Legal Events

Date Code Title Description
8364 No opposition during term of opposition